Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis.

摘要: BACKGROUND The elucidation of new therapeutic targets prognostic significance in colon carcinoma is necessary to improve outcomes. In the current study, authors examined expression epidermal growth factor receptor (EGFR) and vascular endothelial (VEGF) primary cases VEGF tumor-associated macrophages (TAM)/stroma, their correlation with survival. METHODS The identified 131 consecutive American Joint Committee on Cancer Stage II III patients seen at University Rochester between 1990–1995. Expression VEGF, EGFR, CD68 were by immunohistochemistry paraffin-embedded tumors graded as percentage cells stained. Data analyzed using a multivariate Cox proportional hazards model. RESULTS VEGF tumor was not found be significantly associated survival. However, 42% expressed TAM/stroma. The median survival this group 9.7 years versus 4.3 VEGF-negative (TAM/stroma) (hazards ratio 0.57, 95% confidence interval [95% CI], 0.34–0.95; P = 0.03). Although TAM infiltration alone significant analysis, presence both predictive improved 0.48, CI, 0.28–0.83; 0.006). High grades EGFR (≥ Grade 2) trend toward worsened survival. CONCLUSIONS The greater than twofold increase VEGF-expressing suggests hitherto unknown role for subset host response requires further investigation. Overexpression may survival, providing rationale trials anti-EGFR agents adjuvant therapy. 2003;97:960–8. © 2003 Society. DOI 10.1002/cncr.11152